TickerTalks
Browse all tickers →
TickerTalks›$ISRG
ISISRG

Intuitive Surgical, Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 23% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (211/wk), no spike
$ISRG·$134B·Medical - Instruments & Supplies·Healthcare
$376.86+1.1%YTD-35.0%1Y-21.4%
Mentions · last 7 days
2026-08-22: 17 posts2026-08-23: 29 posts211+5%
Price updated 7h ago·X counts updated 8d ago
ISISRG
$ISRGIntuitive Surgical, Inc.
$376.86+1.14%211 posts+5%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ISRG, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptWinding up for a moveAI verdict · as of 2026-08-30

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

The dominant surgical-robot company down 35% YTD despite 23% revenue growth — the multi-year compounder just went on sale.

Intuitive Surgical makes the da Vinci robotic-surgery system — the near-monopoly platform in soft-tissue surgery — plus the consumables and services attached to every procedure. It's had a brutal 2025 sell-off despite the business itself never slowing.

Why the setup matters:

  • Re-rating is severe, business is fine: shares down 35% YTD and 21% over 12 months, at only the 16th percentile of the 52-week range and 21% below the 200-day — a compounder-quality name pricing problems it doesn't have.
  • Operating engine is firing: Q1 revenue grew 23% year-on-year to $2.77B and operating margin at 31% — for a robot at $2M+ per unit plus per-procedure consumables, the kind of print that separates quality medical device.
  • Valuation has room: 50x trailing earnings, 39x EV/EBITDA and 14x sales — still not cheap, but for a 23%-grower with 16% ROIC and near-monopoly pricing power, a real discount to 12 months ago.
  • Pricing power intact: 'ISRG costs him more and he buys anyway' from a former HCA CDO is exactly the anecdote you want for a razor-and-blades business; record cash flow supports next-gen R&D.
  • Insider signal is small: Brosius sold ~$120K across four filings — programmatic, not a distribution cluster.

The October 20 print breaks the coil — procedure volume growth staying above 15% plus next-gen platform cadence lifts the multiple; a bariatric-surgery volume slowdown (GLP-1 headwind) or fresh pricing-pressure commentary keeps ISRG rangebound near $370.

Agrees with X sentimentAgree — the bull anchors (record cash flow supporting R&D, pricing power tell, quality-companies-don't-stay-cheap framing, robotics/automation 2030 thesis) all map to real signals; the honest add is the -35% YTD is severe and that only breaks on a specific procedure-volume re-acceleration, not just multiple expansion.

What to watch: October 20 earnings — the specific numbers are da Vinci procedure volume growth (needs to stay above 15%) and next-gen platform launch commentary; a bariatric-surgery volume slowdown (GLP-1 headwind) is the specific risk that keeps ISRG rangebound.

On the calendar: 2026-10-20 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment25 posts analyzed · as of 2026-08-31

Long-term holders frame ISRG as a quality compounder trading at its cheapest earnings yield since 2016, with the stock "under $400" called "a steal" and 33x forward earnings its lowest in five years. Posters lean on the widening da Vinci moat (installed base, trained staff, 20M-procedure AI training corpus) and pricing power from customer ROI. A parallel thread is noise from BingX listing ISRG perpetual futures alongside MO, SPOT, AMGN and LIN.

Read the AI verdict + X sentiment for $ISRG

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes the da Vinci robotic surgery system, earning recurring revenue from instruments and service contracts.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Instruments & Supplies sits in its cycle right now — and what that implies for $ISRG.

Medical - Instruments & Supplies · Healthcare

Life science tools demand is tied to pharma/biotech R&D budgets; GLP-1 clinical development is a current bright spot driving CRO and instrument demand. Academic and government research funding is the more volatile demand component.

What this means for $ISRG

Partial — software subscription economics provide some insulation from macro cycles; AI integration is the growth catalyst for this segment; Intuitive Surgical, Inc.

Industry benchmark

10-name peer basket
+24.6%YTD
+27.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
50.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
16.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
30.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
1.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
14.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
17.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
66.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 16, 2026$2.80$2.48+12.9%
Q1 2026Apr 21, 2026$2.80$2.51+11.6%
Q4 2025Jan 22, 2026$2.53$2.27+11.5%
Q3 2025Oct 21, 2025$2.40$1.99+20.6%
Next earningsTue, Oct 20·consensus EPS $2.61

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$2.8B+23.0%66.1%30.9%$2.31$808.6M
Q4 FY25$2.9B+18.8%66.4%30.2%$2.24$730.0M
Q3 FY25$2.5B+22.9%66.4%30.3%$1.98$735.6M
Q2 FY25$2.4B+21.4%66.3%30.5%$1.84$560.1M

Forward consensus

5-year forecast · up to 26 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$11.8B$11.4B – $12.4B$10.80$10.49 – $10.9524
FY27$13.3B$12.8B – $13.9B$12.08$11.85 – $12.7025
FY28$15.0B$13.4B – $16.3B$13.60$11.97 – $14.9626
FY29$16.8B$16.1B – $17.8B$15.60$14.68 – $16.7425
FY30$18.5B$17.7B – $19.5B$17.00$16.00 – $18.2415

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.18%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-1.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-19.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 351.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.465-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 21Mark BrosiusEVP & Chief Mfg and Supply Cha77 sh$29KSellAug 20Mark BrosiusEVP & Chief Mfg and Supply Cha77 sh$31KSellAug 19Mark BrosiusEVP & Chief Mfg and Supply Cha77 sh$30KSellAug 18Mark BrosiusEVP & Chief Mfg and Supply Cha77 sh$30KSellAug 17Mark BrosiusEVP & Chief Mfg and Supply Cha77 sh$30KSellAug 11Gary S GuthartDirector10.0K sh$4.0MSellAug 11Amy L LaddDirector72 sh$28KSellAug 10Amy L LaddDirector400 sh$152KSellAug 10Gary LoebEVP & Chief Legal and Complian400 sh$152KSellJul 31Mark BrosiusEVP & Chief Mfg and Supply Cha28 sh$10K
1–10 of 33
+ 24 other (13 exempts · 9 awards · 2 inkinds) in window

See when $ISRG insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KCharter amendmentJul 278-K — Item 5.03: Charter amendment
AI summary

ISRG amended its articles of incorporation or bylaws. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Governance document amendments affect shareholder rights and corporate rules, and Item 5.03 requires prompt public disclosure of any such material changes.

8-KOfficer or director changeMay 288-K — Item 5.02: Officer or director change
AI summary

Intuitive Surgical, Inc. announced that Henry L. Charlton will transition from his role as Chief Commercial and Marketing Officer to Senior Vice President of Global Business Operations effective July 1, 2026. Taylor Patton, currently Global SVP Endoluminal, will succeed Charlton as the Company's new Chief Commercial and Marketing Officer. The leadership change appears to be an orderly internal transition with no indication of disagreement, and reflects the company's continued commercial expansion in surgical robotics.

8-KOfficer or director changeMay 48-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote · Item 7.01: Press release / Reg FD
AI summary

ISRG disclosed a personnel change (8-K Item 5.02, dated 2026-05-04). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

+ 11 other (2 10-Qs · 2 earnings 8-Ks · 2 13Gs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Intuitive Surgical, Inc. (ISRG) Gains As Market Dips: What You Should Knowzacks.com·3d agoIntuitive Surgical's Record Cash Flow Gives It an Innovation Advantagezacks.com·5d agoISRG vs. MDT: Which Surgical Robot Stock Is the Smarter Buy?zacks.com·6d agoWall Street Bulls Look Optimistic About Intuitive Surgical (ISRG): Should You Buy?zacks.com·8d agoIntuitive Surgical Expands Manufacturing Footprint in Asia Pacificzacks.com·13d ago

In themes

Explore the broader themes this ticker is being talked about under.

Robotics & Humanoids

More in Medical - Instruments & Supplies

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BDX$MDLN$AVTR$QDEL$RGEN$WST$PLSE$BLFS
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport